Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

7.1%

1 terminated/withdrawn out of 14 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

21%

3 trials in Phase 3/4

Results Transparency

50%

4 of 8 completed trials have results

Key Signals

3 recruiting4 with results

Enrollment Performance

Analytics

N/A

4(33.3%)

Phase 2

4(33.3%)

Phase 3

3(25.0%)

Phase 1

1(8.3%)

12Total

N/A(4)

Phase 2(4)

Phase 3(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials

NCT06101784Phase 1Completed

Single and Multiple Ascending Oral Doses of Avenanthramide

Role: collaborator

NCT05918861Phase 3Recruiting

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Role: collaborator

NCT04970888Not ApplicableRecruiting

Comparing the Effects of Combining Cognitive and Physical Exercise Training on Cognition, and Cerebral Blood Flow Regulation in Men and Women With Chronic Heart Failure

Role: collaborator

NCT02387229Phase 3Terminated

Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF

Role: collaborator

NCT04962061Not ApplicableRecruiting

A Combined Multidomain Intervention to Prevent Cognitive Decline Associated With Cardiovascular Risk Factors.

Role: collaborator

NCT04467905Phase 2Completed

ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2

Role: collaborator

NCT03857256Phase 2Completed

Compare the Efficacy and Safety of Beta-Glucan as Add-On to Statin in Subjects With Hyperlipidemia.

Role: collaborator

NCT05223426Not ApplicableUnknown

Effects of Individualized Cognitive Training on Cognition in Heart Failure

Role: collaborator

NCT05212831Not ApplicableCompleted

Portable Oxygen Concentrator (POC) Versus Standard of Care in Long-COVID: Randomized Crossover Exploratory Pilot Study.

Role: collaborator

NCT04676867Phase 2Completed

Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19

Role: collaborator

NCT02525939Phase 3Completed

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

Role: collaborator

NCT03239366Phase 2Unknown

A Study to Evaluate the Effect of BioK+ 50B® on Glycemic Control in a Type 2 Diabetes Population

Role: collaborator

NCT02831907Completed

Portal Flow Pulsatility as a Risk Factor for Acute Kidney Injury After Cardiac Surgery

Role: collaborator

NCT02658006Completed

Evaluation of Monitoring TECHNOlogies in the PERI-OPerative Care of Cardiac Surgical Patients

Role: collaborator

All 14 trials loaded